NCT07149090 2025-11-20
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites
Asan Medical Center
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06157996 2025-05-30
Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT06748508 2024-12-27
FDZL-GC003
Fudan University
Phase 2 Not yet recruiting
NCT04745988 2024-11-15
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT06499610 2024-07-12
Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 4 Not yet recruiting
NCT06383559 2024-04-25
Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06277024 2024-02-26
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Fujian Medical University
Phase NA Recruiting
NCT04519151 2023-06-08
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
Phase 2 Recruiting